NSCM
RPRX icon

New South Capital Management’s Royalty Pharma RPRX Stock Holding History

New South Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134M Sell
2,385,943
-239,920
-9% -$12.5M 5.87% 4
2026
Q1 		$126M Sell
2,625,863
-302,915
-10% -$13.3M 6.04% 5
2025
Q4 		$113M Buy
2,928,778
+10,515
+0.4% +$401K 5.21% 5
2025
Q3 		$103M Buy
2,918,263
+31,694
+1% +$1.15M 4.69% 5
2025
Q2 		$104M Sell
2,886,569
-20,900
-0.7% -$692K 5.04% 5
2025
Q1 		$90.5M Sell
2,907,469
-49,656
-2% -$1.57M 4.36% 6
2024
Q4 		$75.4M Buy
2,957,125
+490,754
+20% +$13M 3.18% 7
2024
Q3 		$69.8M Buy
2,466,371
+117,394
+5% +$3.25M 2.85% 9
2024
Q2 		$61.9M Buy
2,348,977
+887,522
+61% +$24.6M 2.77% 11
2024
Q1 		$44.4M Buy
+1,461,455
New +$43.1M 1.86% 18

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

New South Capital Management's RPRX Position: Q2 2026 in Review

New South Capital Management reduced its Royalty Pharma (RPRX) stake by 9.1% in Q2 2026, selling an estimated $12.5M and leaving 2,385,943 shares worth $134M. The position accounts for 5.87% of the portfolio, ranked #4.

New South Capital Management first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • New South Capital Management held 2,385,943 shares of Royalty Pharma worth $134M as of Q2 2026.
  • New South Capital Management sold 239,920 Royalty Pharma shares in Q2 2026, an estimated $12.5M.
  • Royalty Pharma made up 5.87% of New South Capital Management's portfolio in Q2 2026, its #4 holding.
  • New South Capital Management first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on New South Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.